Open Orphan: creating a valuable niche
Open Orphan (ORPH) presents an opportunity to invest in a company targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market, which is growing at around 11% a year, around twice as fast as the global pharmaceuticals market. At the same time, there is a great disparity between the US and Europe in the number of orphan drugs on the market, which reflects an unmet need in the market for specialist services to help address the balance.
ORPH is addressing the opportunity within the pharma services market to create shareholder value by combining a number of smaller consultancies focused on the orphan and rare disease space, extracting both top-line and cost synergies. The company targets organic revenue growth as well as building critical mass from strategic acquisitions at favourable enterprise value/sales multiples.
Quick facts: Open Orphan
Market Cap: £15.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan named herein, including the promotion by the Company of Open Orphan in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE